Evidence map›Paper›PMID 35708742›Full record

ArticleJMIR research protocols2022

Ensuring a Successful Transition From Cytology to Human Papillomavirus-Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Women's Intentions: Protocol for an Observational Study.

Gabrielle Griffin-Mathieu, Ben Haward, Ovidiu Tatar, Patricia Zhu, Samara Perez, Gilla K Shapiro, Emily McBride, Erika L Thompson, Laurie W Smith, Aisha K Lofters and 11 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Gabrielle Griffin-Mathieu *Lady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-6169-2747
Ben Haward *Lady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-6119-5767
Ovidiu TatarLady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0003-1886-6390
Patricia ZhuLady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0001-6549-3668
Samara PerezLady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-4849-8616
Gilla K ShapiroDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-2214-8263
Emily McBrideDepartment of Behavioural Science & Health, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-9926-429X
Erika L ThompsonDepartment of Biostatistics and Epidemiology, School of Public Health, The University of North Texas Health Science Center, Fort Worth, TX, United States.ORCID https://orcid.org/0000-0002-7115-0001
Laurie W SmithBC Cancer Agency, Vancouver, BC, Canada.ORCID https://orcid.org/0000-0002-9463-1713
Aisha K LoftersDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-7322-0894
Ellen M DaleyCollege of Public Health, University of South Florida, Tampa, FL, United States.ORCID https://orcid.org/0000-0003-3020-295X
Juliet R GuichonDepartment of Community Health Sciences, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0003-0537-4215
Jo WallerSchool of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4025-9132
Marc StebenHPV Global Action, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-1136-3208
Kathleen M DeckerDepartment of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.ORCID https://orcid.org/0000-0002-0044-7545
Marie-Helene MayrandResearch Center, Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-1073-6199
Julia M L BrothertonMelbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.ORCID https://orcid.org/0000-0002-2304-3105
Gina S OgilvieBC Cancer Agency, Vancouver, BC, Canada.ORCID https://orcid.org/0000-0001-5783-4493
Gregory D ZimetSchool of Medicine, Indiana University, Bloomington, IN, United States.ORCID https://orcid.org/0000-0003-3835-937X
Teresa NorrisHPV Global Action, Montreal, QC, Canada.ORCID https://orcid.org/0000-0003-1823-2830
Zeev RosbergerLady Davis Institute for Medical Research, McGill University, Jewish General Hospital, Montreal, QC, Canada.ORCID https://orcid.org/0000-0003-4248-1909

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe human papillomavirus (HPV) test has emerged as a significant improvement over cytology for primary cervical cancer screening. In Canada, provinces and territories are moving toward implementing HPV testing in cervical cancer screening programs. Although an abundance of research exists on the benefits of HPV-based screening, there is a dearth of research examining women's understanding of HPV testing. In other countries, failure to adequately address women's concerns about changes has disrupted the implementation of HPV-based screening.

objectiveThe aims of the multipart study described in this paper are to develop psychometrically valid measures of cervical cancer screening-related knowledge, attitudes, and beliefs; to examine the feasibility of a questionnaire examining psychosocial factors related to HPV-based screening; and to investigate psychosocial correlates of women's intentions to participate in HPV-based screening.

methodsWe conducted a web-based survey (study 1) of Canadian women to assess the acceptability and feasibility of a questionnaire, including the validation of scales examining cervical cancer knowledge, HPV testing knowledge, HPV testing attitudes and beliefs, and HPV test self-sampling attitudes and beliefs. Preferences for cervical cancer screening were assessed using the best-worst scaling methodology. A second web-based survey (study 2) will be administered to a national sample of Canadian women between June 2022 and July 2022 using the validated scales. Differences in the knowledge, attitudes, beliefs, and preferences of women who are currently either underscreened or adequately screened for cervical cancer will be examined through bivariate analyses. Multinomial logistic regression will be used to estimate the associations between psychosocial and sociodemographic factors and intentions to undergo HPV-based screening.

resultsBetween October 2021 and November 2021, a total of 1230 participants completed the questionnaire in study 1, and 1027 (83.49%) responses were retained after data cleaning methods were applied. Feasibility was comparable with similar population-based surveys in terms of survey length, participant attrition, and the number of participants excluded after data cleaning. As of May 2022, analysis of study 1 is ongoing, and results are expected to be published in the summer of 2022. Data collection is expected to begin for study 2 in the summer of 2022. Results are expected to be published between late 2022 and early 2023.

conclusionsFindings will provide direction for Canadian public health authorities to align guidelines to address women's concerns and optimize the acceptability and uptake of HPV-based primary screening. Validated scales can be used by other researchers to improve and standardize the measurement of psychosocial factors affecting HPV test acceptability. Study results will be disseminated through peer-reviewed journal articles; conference presentations; and direct communication with researchers, clinicians, policy makers, media, and specialty organizations. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/38917.

Indexed as

attitudes and beliefscancer preventioncervical cancercervical cancer screeningcytologyHPV-based primary screeningHPV self-samplingHPV test acceptabilityhuman papillomavirusknowledgemobile phonePap testingpreferences

Identifiers

PMID35708742
PMCPMC9247817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.